NSWRC(SH:600165) Xin Lang Cai Jing·2025-12-10 11:16Core Viewpoint - Ningxia Zhongke Biological announced that it has received a total of 1.241 billion yuan from all restructuring investors, which is crucial for its financial recovery [1] Group 1: Financial Developments - The company has received the full amount of restructuring investment from investors, totaling 1.241 billion yuan [1] - Prior to this, Hunan Chuntou and other industrial and financial investors signed pre-restructuring investment agreements with the company and the temporary management [1] Group 2: Risks and Challenges - The company faces the risk of delisting if it fails to execute or cannot execute the restructuring plan, which could lead to bankruptcy and liquidation [1] - There is a possibility that the investment agreements may be terminated or rescinded, posing additional risks to the company [1] - Subsidiaries Zhongke New Materials and Hengli Guotai also face bankruptcy risks if they do not execute the restructuring plan [1]